118 related articles for article (PubMed ID: 7720173)
1. Pharmacokinetic evaluation of zeniplatin in humans.
DeMarco LC; Budman DR; Lathia C; Amorusi P; Birkhofer M; Lichtman S; Weiselberg L; Vinciguerra V; Lovecchio J; Gal D
Cancer Chemother Pharmacol; 1995; 36(1):35-40. PubMed ID: 7720173
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical and pharmacokinetic study of zeniplatin, a new platinum complex.
Dodion PF; de Valeriola D; Crespeigne N; Kantrowitz JD; Piccart M; Wery F; Kerger J; Egorin MJ; Forrest A; Bachur NR
Ann Oncol; 1991 Sep; 2(8):589-96. PubMed ID: 1793726
[TBL] [Abstract][Full Text] [Related]
3. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacokinetics and dose optimisation of carboplatin.
Duffull SB; Robinson BA
Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610
[TBL] [Abstract][Full Text] [Related]
5. The disposition of carboplatin in ovarian cancer patients.
Gaver RC; Colombo N; Green MD; George AM; Deeb G; Morris AD; Canetta RM; Speyer JL; Farmen RH; Muggia FM
Cancer Chemother Pharmacol; 1988; 22(3):263-70. PubMed ID: 3044634
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics of carboplatin.
Oguri S; Sakakibara T; Mase H; Shimizu T; Ishikawa K; Kimura K; Smyth RD
J Clin Pharmacol; 1988 Mar; 28(3):208-15. PubMed ID: 3283185
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of zeniplatin (CL 286,558), a new patinum compound, in patients with advanced ovarian cancer previously treated with organoplatinum-based therapy.
Markman M; DeMarco LC; Birkhofer M; Budman D; Hakes T; Reichman B; Rubin S; Jones W; Barakat R; Curtin J
J Cancer Res Clin Oncol; 1993; 119(4):234-6. PubMed ID: 8423199
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of carboplatin after i.v. administration.
Elferink F; van der Vijgh WJ; Klein I; Vermorken JB; Gall HE; Pinedo HM
Cancer Treat Rep; 1987 Dec; 71(12):1231-7. PubMed ID: 3319135
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of (glycolate-0,0')-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin.
Sasaki Y; Tamura T; Eguchi K; Shinkai T; Fujiwara Y; Fukuda M; Ohe Y; Bungo M; Horichi N; Niimi S
Cancer Chemother Pharmacol; 1989; 23(4):243-6. PubMed ID: 2647312
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels.
Ghazal-Aswad S; Tilby MJ; Lind M; Baily N; Sinha DP; Calvert AH; Newell DR
Ann Oncol; 1999 Mar; 10(3):329-34. PubMed ID: 10355578
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of carboplatin at a dose of 750 mg m-2 divided over three consecutive days.
Mulder PO; de Vries EG; Uges DR; Scaf AH; Sleijfer DT; Mulder NH
Br J Cancer; 1990 Mar; 61(3):460-4. PubMed ID: 2183874
[TBL] [Abstract][Full Text] [Related]
12. A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve.
Ghazal-Aswad S; Calvert AH; Newell DR
Cancer Chemother Pharmacol; 1996; 37(5):429-34. PubMed ID: 8599865
[TBL] [Abstract][Full Text] [Related]
13. A phase II and pharmacokinetic study of enloplatin in patients with platinum refractory advanced ovarian carcinoma.
Kudelka AP; Siddik ZH; Tresukosol D; Edwards CL; Freedman RS; Madden TL; Rastogi R; Hord M; Kim EE; Tornos C; Mante R; Kavanagh JJ
Anticancer Drugs; 1997 Aug; 8(7):649-56. PubMed ID: 9311439
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of the novel platinum analogue CI-973 on a 5-daily dose schedule.
O'Dwyer PJ; Hudes GR; Walczak J; Schilder R; LaCreta F; Rogers B; Cohen I; Kowal C; Whitfield L; Boyd RA
Cancer Res; 1992 Dec; 52(24):6746-53. PubMed ID: 1458462
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and phase I trial of intraperitoneal carboplatin and cyclosporine in refractory ovarian cancer patients.
Chambers SK; Chambers JT; Davis CA; Kohorn EI; Schwartz PE; Lorber MI; Handschumacher RE; Pizzorno G
J Clin Oncol; 1997 May; 15(5):1945-52. PubMed ID: 9164206
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacokinetic study of intraperitoneal chemotherapy with high-dose cisplatin for advanced ovarian cancer].
Deng C; Huang R; Lian L
Zhonghua Fu Chan Ke Za Zhi; 1996 Mar; 31(3):159-62. PubMed ID: 8758790
[TBL] [Abstract][Full Text] [Related]
17. Zeniplatin in patients with advanced ovarian cancer, a phase II study with a third generation platinum complex.
Willemse PH; Gietema JA; Mulder NH; de Vries EG; Meijer S; Bouma J; Birkhofer M; Rastogi RB; Sleijfer DT
Eur J Cancer; 1993; 29A(3):359-62. PubMed ID: 8398335
[TBL] [Abstract][Full Text] [Related]
18. Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates.
Jacobs SS; Fox E; Dennie C; Morgan LB; McCully CL; Balis FM
Clin Cancer Res; 2005 Feb; 11(4):1669-74. PubMed ID: 15746072
[TBL] [Abstract][Full Text] [Related]
19. Monitoring carboplatin concentrations in saliva: a replacement for plasma ultrafiltrate measurements?
van Warmerdam LJ; van Tellingen O; ten Bokkel Huinink WW; Rodenhuis S; Maes RA; Bijnen JH
Ther Drug Monit; 1995 Oct; 17(5):465-70. PubMed ID: 8585109
[TBL] [Abstract][Full Text] [Related]
20. Amifostine (Ethyol): pharmacokinetic and pharmacodynamic effects in vivo.
van der Vijgh WJ; Korst AE
Eur J Cancer; 1996; 32A Suppl 4():S26-30. PubMed ID: 8976819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
